31Jan 2023
Clinical characteristics and serum CA19‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer

Clinical characteristics and serum CA19‐9 combined with HE4 are valuable in diagnosing endometriosis‐associated ovarian cancer

Endometriosis-associated ovarian cancer (EAOC) is difficult to diagnose as low incidence, uncertain risk factors, and absence of effective markers. This study aimed to investigate the clinical characteristics of EAOC and identify useful serological markers. The study results demonstrated that, EAOC patients were older (46.20 vs. 36.26 years, P < 0.001) and had a larger tumor ((9.10 vs. 6.73 cm, P = 0.003)) along with higher CA19‐9 (21.44 vs. 4.72 U/mL, P < 0.001) and HE4 levels (62.35 vs. 44.19 pmol/L, P < 0.001) when compared to OEM patients. Multivariate analysis showed that HE4 ≥ 59.7 pmol/L, CA19‐9 ≥ 8.5 U/mL, age ≥ 42 years, and tumor length ≥ 9.2 cm were independent risk factors for EAOC. Significantly, CA19‐9 combined with HE4 had high sensitivity (72.73%) and specificity (78.41%) in diagnosing EAOC. Hence, it can be concluded that age over 42 years, large ovarian tumor, serum CA19‐9 and HE4 are valuable in the diagnosis of EAOC.

  • #gynaecology - ivf

Like

Save

Share